Stay updated on GB5121 in Refractory CNS Lymphoma Clinical Trial
Sign up to get notified when there's something new on the GB5121 in Refractory CNS Lymphoma Clinical Trial page.

Latest updates to the GB5121 in Refractory CNS Lymphoma Clinical Trial page
- Check3 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4, indicating a minor system update with no impact on study data or user functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe Locations section was expanded to include new trial sites across the US, Australia, Canada, France, and New Zealand, and the previous site listings were removed. Revision: v3.3.3.SummaryDifference1%

- Check46 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.1; no changes to the study details, page layout, or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check61 days agoChange DetectedThe government funding status notice about operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedNo substantive content changes detected; the page's core details (study design, eligibility criteria, and locations) appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to GB5121 in Refractory CNS Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GB5121 in Refractory CNS Lymphoma Clinical Trial page.